Proteomics in cardiovascular disease: recent progress and clinical implication and implementation M Mokou, V Lygirou, A Vlahou, H Mischak Expert review of proteomics 14 (2), 117-136, 2017 | 45 | 2017 |
Proteome‐based classification of nonmuscle invasive bladder cancer R Stroggilos, M Mokou, A Latosinska, M Makridakis, V Lygirou, ... International Journal of Cancer 146 (1), 281-294, 2020 | 39 | 2020 |
Functional secretome analysis reveals Annexin-A1 as important paracrine factor derived from fetal mesenchymal stem cells in hepatic regeneration D Zagoura, O Trohatou, M Makridakis, A Kollia, N Kokla, M Mokou, ... EBioMedicine 45, 542-552, 2019 | 35 | 2019 |
Proteomics based identification of KDM5 histone demethylases associated with cardiovascular disease M Mokou, J Klein, M Makridakis, V Bitsika, JL Bascands, ... EBioMedicine 41, 91-104, 2019 | 31 | 2019 |
Proteomics analysis of bladder cancer invasion: targeting EIF3D for therapeutic intervention A Latosinska, M Mokou, M Makridakis, W Mullen, J Zoidakis, V Lygirou, ... Oncotarget 8 (41), 69435, 2017 | 31 | 2017 |
Drug repurposing in oncology M Frantzi, A Latosinska, M Mokou, H Mischak, A Vlahou The Lancet Oncology 21 (12), e543, 2020 | 25 | 2020 |
A novel pipeline for drug repurposing for bladder cancer based on patients’ omics signatures M Mokou, V Lygirou, I Angelioudaki, N Paschalidis, R Stroggilos, ... Cancers 12 (12), 3519, 2020 | 11 | 2020 |
BcCluster: A bladder cancer database at the molecular level A Bhat, M Mokou, J Zoidakis, V Jankowski, A Vlahou, H Mischak Bladder Cancer 2 (1), 65-76, 2016 | 5 | 2016 |
Mass Spectrometry-Based Biomarkers to Detect Prostate Cancer: A Multicentric Study Based on Non-Invasive Urine Collection without Prior Digital Rectal Examination M Frantzi, Z Culig, I Heidegger, M Mokou, A Latosinska, MC Roesch, ... Cancers 15 (4), 1166, 2023 | 4 | 2023 |
Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients L Mengual, M Frantzi, M Mokou, M Ingelmo-Torres, M Vlaming, ... British Journal of Cancer 127 (11), 2043-2051, 2022 | 4 | 2022 |
Gene expression monotonicity across bladder cancer stages informs on the molecular pathogenesis and identifies a prognostic eight-gene signature R Stroggilos, M Frantzi, J Zoidakis, M Mokou, N Moulavasilis, ... Cancers 14 (10), 2542, 2022 | 4 | 2022 |
Statistical determination of cancer biomarkers: Moving forward clinically M Mokou, H Mischak, M Frantzi Expert Review of Molecular Diagnostics 23 (3), 187-189, 2023 | 2 | 2023 |
Developing novel drug candidates and repurposed drugs for prostate cancer based on molecular profiles M Mokou, M Frantzi, H Mischak, A Vlahou, A Latosinska Current Medicinal Chemistry 28 (40), 8392-8415, 2021 | 2 | 2021 |
A prospective validation of nomograms based on BC-116 and BC-106 urine peptide biomarker panels for bladder cancer diagnostics and monitoring L Mengual, M Frantzi, M Mokou, M Ingelmo-Torres, M Vlaming, ... medRxiv, 2021.12. 15.21267846, 2021 | 1 | 2021 |
Amiodarone, an anti-arrhythmic drug, is a new repurposed drug for bladder cancer therapy FJ Roa, MG Roubelakis, K Paschidis, NCH Van Creij, M Makridakis, ... European Urology 85, S1905, 2024 | | 2024 |
From multi-omics integrated signatures to repurposed drugs for bladder cancer treatment: The case of cephaeline MJ Hoffmann, M Makridakis, TF Reese, A Latosinska, H Mischak, ... European Urology Open Science 56, S9, 2023 | | 2023 |
Urinary peptides provide information about the risk of mortality across a spectrum of diseases and scenarios F Keller, J Beige, J Siwy, A Mebazaa, D An, H Mischak, JP Schanstra, ... Journal of Translational Medicine 21 (1), 663, 2023 | | 2023 |
A Drug Repurposing Pipeline Based on Bladder Cancer Integrated Proteotranscriptomics Signatures M Mokou, S Narayanasamy, R Stroggilos, IA Balaur, A Vlahou, H Mischak, ... Urothelial Carcinoma: Methods and Protocols, 59-99, 2023 | | 2023 |
Urinary peptides predict future death F Keller, J Beige, J Siwy, A Mebazaa, D An, H Mischak, JP Schanstra, ... medRxiv, 2023.04. 28.23289257, 2023 | | 2023 |
The COV50 classifier predicts frailty and future death, independent from SARS-CoV-2 infection F Keller, J Beige, J Siwy, A Mebazaa, D An, H Mischak, JP Schanstra, ... | | 2023 |